Current Headlines

  1. ISPE Hires Healthcare Association Exec As Ceo
    7/30/2014

    ISPE—the International Society for Pharmaceutical Engineering announced today it has hired John Bournas as President and CEO, succeeding Nancy Berg who announced plans to leave the Society last fall. 

  2. Ziopharm Develops Cancer Drugs With On-Off Switch
    7/30/2014
    Biopharmaceutical firm Ziopharm Oncology announced that it has expanded its synthetic immuno-oncology programs with Intrexon Corp to develop cancer drugs that can be ‘switched’ on or off with an oral pill.
  3. J&J And Organovo Link For 3D-Printing Drug Discovery
    7/30/2014

    Johnson & Johnson company Janssen Research and Development announced that it is has entered into collaboration with bioprinting firm Organovo to investigate 3D printing of living tissue for drug discovery and research.

  4. Scientists ‘Snip’ HIV From Cultured Human Cells
    7/29/2014

    Scientists from Temple University reported that they have designed a new approach to remove HIV from human cells growing in culture through genome editing.

  5. Gilead’s Zydelig Approved By FDA For 3 Blood Cancers
    7/29/2014
    The U.S. Food and Drug Administration (FDA) announced that it has approved Gilead Sciences’ Zydelig for the treatment of three types of blood cancers.
  6. AstraZeneca, Qiagen Partner For IRESS Companion Test In NSCLC
    7/29/2014
    Netherlands-based sample and assays technologies company Qiagen announced that it has entered into partnership with British pharma giant AstraZeneca for the development and marketing of a liquid biopsy-based companion diagnostic for Iressa, AstraZeneca’s drug for non-small cell lung cancer (NSCLC).
  7. Researchers Pinpoint Mechanism In Malaria Drug Resistance
    7/28/2014

    Researchers from the Washington University School of Medicine in St. Louis reported their discovery of a mechanism behind malaria parasites’ drug resistance. The discovery may also apply to other infectious diseases, such as tuberculosis and bacterial infections.

  8. CHMP Recommends Pharmacyclics’ Imbruvica For 2 Blood Cancers
    7/28/2014

    Pharmacyclics announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for its marketing authorization application for Imbruvica (ibrutinib) in the EU.

  9. Grace Launches New REVELERIS® Prep Purification System
    7/28/2014

    W. R. Grace & Co. announces recently the release of the REVELERIS® Prep purification system, a dual-mode instrument that allows organic chemists, preparative chromatographers, and other researchers to perform both flash and preparative liquid chromatography (LC) using a single unit.

  10. Shire Partners With ArmaGen On AGT-182 For Hunter Syndrome
    7/25/2014

    Shire announced in a press release that it has partnered with ArmaGen, a U.S. biotechnology company, on AGT-182 for Hunter syndrome. The investigational enzyme replacement therapy (ERT) has potential in treating the central nervous system (CNS) symptoms of the rare disease. Shire states that the new collaboration demonstrates its commitment to the Hunter syndrome community and strengthens its rare disease pipeline.

Newsletter Signup
Newsletter Signup